Prognostically Significant Myocardial Injury in Patients Undergoing Transcatheter Aortic Valve Replacement.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
16 07 2019
Historique:
entrez: 4 7 2019
pubmed: 4 7 2019
medline: 13 11 2020
Statut: ppublish

Résumé

Background Troponin elevation occurs commonly in the setting of transcatheter aortic valve replacement (TAVR). There is a lack of information on the extent of troponin elevation post TAVR that is prognostically significant. We assessed the optimal cutoff for post-TAVR troponin T elevation that correlates with long-term mortality. We also examined the relationship between coronary artery disease (CAD) and prognostically significant myocardial injury in TAVR. Methods and Results This is a retrospective, observational single-center study involving patients who underwent TAVR at Cleveland Clinic between 2010 and 2015. Five hundred ten patients were included (mean follow-up of 2.6±1.3 years). Receiver operating characteristic analysis showed that troponin T elevation ≥3× upper limit of normal was the best predictor of long-term mortality post TAVR with area under the curve of 0.57, with transapical TAVR patients excluded. Multivariate analyses confirmed that troponin T elevation ≥3× upper limit of normal was significantly associated with increased long-term mortality post TAVR (hazard ratio 1.57, CI 1.04-2.38, P=0.03). The most common causes for the presence of unrevascularized CAD included the presence of chronic total occlusion in the native/graft vessels (49.7%) and diffuse/complex CAD unsuitable for PCI (24.6%). The presence of unrevascularized CAD and significant left main disease correlated with increased mortality, but not with the presence of prognostically significant myocardial injury. Conclusions Troponin T elevation of ≥3× upper limit of normal is associated with increased long-term mortality after TAVR, except for the transapical approach. This prognostically significant myocardial injury does not appear to be secondary to severe CAD/unrevascularized CAD or left main disease, but rather is associated with other factors such as post-TAVR complications.

Identifiants

pubmed: 31267799
doi: 10.1161/JAHA.118.011889
pmc: PMC6662140
doi:

Substances chimiques

Troponin T 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e011889

Références

Stat Med. 2009 Aug 30;28(19):2473-89
pubmed: 19472308
J Am Coll Cardiol. 2011 May 17;57(20):1988-99
pubmed: 21565636
J Am Coll Cardiol. 1985 May;5(5):1055-63
pubmed: 3989116
J Am Coll Cardiol. 2015 Nov 10;66(19):2075-2088
pubmed: 26541917
Am J Cardiol. 2013 May 1;111(9):1337-43
pubmed: 23415511
J Am Heart Assoc. 2017 Oct 11;6(10):
pubmed: 29021275
Br Heart J. 1977 Jul;39(7):733-9
pubmed: 884023
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23
pubmed: 23084102
Circ Cardiovasc Interv. 2012 Jun;5(3):415-23
pubmed: 22668556
J Am Heart Assoc. 2016 Feb 19;5(2):
pubmed: 26896474
JACC Cardiovasc Interv. 2015 Sep;8(11):1468-79
pubmed: 26404200
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Lancet. 2016 May 28;387(10034):2218-25
pubmed: 27053442
Ann Thorac Surg. 2010 Mar;89(3):758-67; discussion 767
pubmed: 20172123
EuroIntervention. 2016 Apr 20;11(13):1522-9
pubmed: 25671517
Eur Heart J. 2017 Aug 14;38(31):2392-2407
pubmed: 28821170
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
JACC Cardiovasc Interv. 2016 Feb 22;9(4):355-363
pubmed: 26803420
J Am Coll Cardiol. 2014 Jul 15;64(2):158-68
pubmed: 25011720
Int J Cardiol. 2013 Oct 3;168(3):2528-32
pubmed: 23628298
J Am Heart Assoc. 2017 Feb 20;6(2):
pubmed: 28219920
Ann Thorac Surg. 2015 Jun;99(6):2001-9
pubmed: 25863732
J Am Coll Cardiol. 2013 Jul 2;62(1):1-10
pubmed: 23644089
J Am Heart Assoc. 2019 Jul 16;8(14):e011889
pubmed: 31267799
EuroIntervention. 2015 Aug;11(4):450-5
pubmed: 24832041

Auteurs

Vikram Sharma (V)

1 Department of Hospital Medicine The Cleveland Clinic Cleveland OH.

Tanujit Dey (T)

2 Department of Quantitative Health Sciences Lerner Research Institute The Cleveland Clinic Cleveland OH.

Kesavan Sankaramangalam (K)

3 Department of Cardiovascular Medicine, Heart and Vascular Institute The Cleveland Clinic Cleveland OH.

Shehab A R Alansari (SAR)

4 Department of Internal Medicine The Cleveland Clinic Cleveland OH.

Louis Williams (L)

4 Department of Internal Medicine The Cleveland Clinic Cleveland OH.

Stephanie Mick (S)

5 Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute The Cleveland Clinic Cleveland OH.

Amar Krishnaswamy (A)

3 Department of Cardiovascular Medicine, Heart and Vascular Institute The Cleveland Clinic Cleveland OH.

Lars G Svensson (LG)

5 Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute The Cleveland Clinic Cleveland OH.

Samir Kapadia (S)

3 Department of Cardiovascular Medicine, Heart and Vascular Institute The Cleveland Clinic Cleveland OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH